Business
Cannabics Pharmaceuticals Files Patent Application on Cannabinoid Modulation of the Microbiome
Cannabics Pharmaceuticals Files Patent Application on Cannabinoid Modulation of the Microbiome.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Files Patent Application on Cannabinoid Modulation of the Microbiome\n\n\n\n\n\nCannabics Pharmaceuticals Files Patent Application on Cannabinoid Modulation of the Microbiome\nPR Newswire\nTEL-AVIV, Israel, November 8, 2017\n\n\n\nTEL-AVIV, Israel, November 8, 2017 /PRNewswire/ --\n\nCannabics Pharmaceuticals Inc. (CNBX) announced today that it has filed the first of a cluster of patent applications with the US Patent & Trademark Office (USPTO) which covers their ongoing work on the use of cannabinoid products for adjusting the varied microbial populations that live on and in the body.\n\n     (Logo: http://mma.prnewswire.com/media/485543/Cannabics_Logo.jpg )\n\n\nThe pioneering work based on profiling and modulating patient-derived microbiota, personalizes and profiles individual health status. This will make possible the optimization of pharmacological treatments for patients.\n\nDr. Moran Grinberg, VP of R&D of Cannabics Pharmaceuticals said \"Our new integrated approach will allow patients and practitioners to receive a more accurate, personalized result pertaining to their particular individual status. Today we are at the midst of a technological revolution that combines algorithms predicting medical treatment that is based on cumulative clinical data. Therefore, we believe that the integration of multi-system data derived from our screening technologies will provide a comprehensive overview on the patient`s condition\".\n\nAbout Cannabics Pharmaceuticals Inc. \nCannabics Pharmaceuticals Inc. (CNBX), a U.S based public company, is dedicated to the development of Personalized Anti-Cancer and Palliative treatments. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company's focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics engages in developing individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.\n\nDisclaimer: \nCertain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are...